Search Results - "Fong, Chun Y."

Invasive fungal infection following venetoclax and posaconazole co‐administration by Reynolds, Gemma, Urbancic, Karen F., Fong, Chun Y., Trubiano, Jason A.

“…Summary The co‐administration of venetoclax, a BCL‐2 inhibitor, with a mould‐active azole, such a posaconazole, has potential to both prevent invasive fungal…”
Get full text

Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology by Ma, Stephen B., Lin, Wendi, Campbell, Janine, Clerici, Kerrie, White, Deborah, Yeung, David, Gorniak, Malgorzata, Fleming, Shaun, Fong, Chun Y., Agarwal, Rishu

“…Measurable residual disease (MRD) testing is an essential aspect of disease prognostication in acute lymphoblastic leukaemia (ALL) and informs clinical…”
Get full text

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC) by Tiong, Ing Soo, Hiwase, Devendra K, Abro, Emad, Bajel, Ashish, Palfreyman, Emma, Beligaswatte, Ashanka, Reynolds, John, Anstee, Natasha, Nguyen, Tamia, Loo, Sun, Chua, Chong Chyn, Ashby, Michael, Wiltshire, Kaitlyn M, Fleming, Shaun, Fong, Chun Y, Teh, Tse-Chieh, Blombery, Piers, Dillon, Richard, Ivey, Adam, Wei, Andrew H

“…A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual…”
Get full text

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy by Othman, Jad, Tiong, Ing S, O'Nions, Jenny, Dennis, Mike, Mokretar, Katya, Ivey, Adam, Austin, Michael, Latif, Anne-Louise, Amer, Mariam, Chan, Wei Yee, Crawley, Charles, Crolla, Francesca, Cross, Joe, Dang, Ray, Elliot, Johnathon, Fong, Chun Y, Galli, Sofia, Gallipoli, Paolo, Hogan, Francesca, Kalkur, Pallavi, Khan, Anjum, Krishnamurthy, Pramila, Laurie, John, Loo, Sun, Marshall, Scott, Mehta, Priyanka, Murthy, Vidhya, Nagumantry, Sateesh, Pillai, Srinivas, Potter, Nicola, Sellar, Rob, Taylor, Tom, Zhao, Rui, Russell, Nigel H, Wei, Andrew H, Dillon, Richard

“…Assessment of measurable residual disease (MRD) by quantitative reverse transcription polymerase chain reaction is strongly prognostic in patients with…”
Get full text

Outcomes of non‐myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission by Nguyen, Phillip C., Manos, Kate, Fong, Chun Y., Schwarer, Anthony P., Tiong, Ing S., Wei, Andrew H., Kliman, David, Curtis, David J.

“…The benefits of non‐myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. We compare the long‐term outcomes of this…”
Get full text

Experience of the first adult-focussed undiagnosed disease program in Australia (AHA-UDP): solving rare and puzzling genetic disorders is ageless by Wallis, Mathew, Bodek, Simon D, Munro, Jacob, Rafehi, Haloom, Bennett, Mark F, Ye, Zimeng, Schneider, Amy, Gardiner, Fiona, Valente, Giulia, Murdoch, Emma, Uebergang, Eloise, Hunter, Jacquie, Stutterd, Chloe, Huq, Aamira, Salmon, Lucinda, Scheffer, Ingrid, Eratne, Dhamidhu, Meyn, Stephen, Fong, Chun Y, John, Tom, Mullen, Saul, White, Susan M, Brown, Natasha J, McGillivray, George, Chen, Jesse, Richmond, Chris, Hughes, Andrew, Krzesinski, Emma, Fennell, Andrew, Chambers, Brian, Santoreneos, Renee, Le Fevre, Anna, Hildebrand, Michael S, Bahlo, Melanie, Christodoulou, John, Delatycki, Martin, Berkovic, Samuel F

“…Significant recent efforts have facilitated increased access to clinical genetics assessment and genomic sequencing for children with rare diseases in many…”
Get full text

Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients by Thomson, Ashlee J., Rehn, Jacqueline A., Heatley, Susan L., Eadie, Laura N., Page, Elyse C., Schutz, Caitlin, McClure, Barbara J., Sutton, Rosemary, Dalla-Pozza, Luciano, Moore, Andrew S., Greenwood, Matthew, Kotecha, Rishi S., Fong, Chun Y., Yong, Agnes S. M., Yeung, David T., Breen, James, White, Deborah L.

“…B-cell acute lymphoblastic leukaemia (B-ALL) is characterised by diverse genomic alterations, the most frequent being gene fusions detected via transcriptomic…”
Get full text

Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals by Chua, Chong C., Grigg, Andrew, Singh, Jasmine, Droogleever, Mark P., Zhang, Lan, Lim, Andrew, Fong, Chun Y., Ting, Stephen B., Schwarer, Anthony, Tiong, Ing S., Wei, Andrew H.

“…Recent regulatory approval of midostaurin, a FLT3 targeting small molecular inhibitor, will likely lead to increased use of midostaurin in combination with…”
Get full text

Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse by Lim, Andrew B. M., Curley, Cameron, Fong, Chun Y., Bilmon, Ian, Beligaswatte, Ashanka, Purtill, Duncan, Getta, Bartlomiej, Johnston, Anne M., Armytage, Tasman, Collins, Marnie, Mason, Kate, Fielding, Katherine, Greenwood, Matthew, Gibson, John, Hertzberg, Mark, Wright, Matthew, Lewis, Ian, Moore, John, Curtis, David, Szer, Jeff, Kennedy, Glen, Ritchie, David

“…Background/Aims We sought to determine factors associated with the overall survival from relapse (OSR) of acute myeloid leukaemia (AML) after allogeneic…”
Get full text

NGS-based clonality testing is a sensitive and complementary method for MRD monitoring in acute lymphoblastic leukaemia by Ma, Stephen B., Lin, Wendi, Hogan, Chris, Fong, Chun Y., Agarwal, Rishu

Get full text

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia by Loo, Sun, Potter, Nicola, Ivey, Adam, O'Nions, Dr, Jenny, Moon, Roderick, Jovanovic, Jelena, Fong, Chun Yew, Anstee, Natasha S, Tiong, Ing S, Othman, Jad, Chua, Chong Chyn, Renshaw, Hannah, Baker, Robert, Fleming, Shaun, Russell, Nigel H, Ritchie, David, Bajel, Ashish, Hou, Hsin-An, Dillon, Richard James, Wei, Andrew H

“…Pre-transplant detection of KMT2Ar MRD ≥0.001% by quantitative PCR was associated with significantly inferior post-transplant survival (2-year RFS 17% vs 59%;…”
Get full text

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG by Loo, Sun, Roberts, Andrew W., Anstee, Natasha S., Kennedy, Glen, He, Simon, Schwarer, Anthony P., Enjeti, Anoop K., D’Rozario, James, Marlton, Paula, Bilmon, Ian, Taper, John, Cull, Gavin, Tiley, Campbell, Verner, Emma, Hahn, Uwe, Hiwase, Devendra, Iland, Harry J., Murphy, Nick, Ramanathan, Sundra, Reynolds, John, Ong, Doen Ming, Tiong, Ing S., Wall, Meaghan, Murray, Michael, Rawling, Tristan, Leadbetter, Joanna, Rowley, Leesa, Latimer, Maya, Yuen, Sam, Ting, Stephen B., Fong, Chun Y., Morris, Kirk, Bajel, Ashish, Seymour, John F., Levis, Mark J., Wei, Andrew H.

“…•Sorafenib did not significantly improve the EFS when added to intensive chemotherapy for newly diagnosed FLT3-ITD AML.•FLT3-ITD MRD clearance as assessed by…”
Get full text

Comparison of Frontline Induction Therapy Using Idarubicin in Combination with High-Dose (HDAC3) Versus Intermediate-Dose Cytarabine (IDAC3) in Adult Acute Myeloid Leukemia by Tiong, Ing Soo S, Fielding, Katherine, Fong, Chun Y, Bortz, Hadley, Avery, Sharon, Grigg, Andrew P, Wei, Andrew

“…Background The utility of high-dose cytarabine during induction chemotherapy for adult acute myeloid leukemia (AML) remains contentious. Intermediate-dose…”
Get full text

Reproducible Bioinformatics Analysis Workflows for Detecting IIGH/I Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients by Thomson, Ashlee J, Rehn, Jacqueline A, Heatley, Susan L, Eadie, Laura N, Page, Elyse C, Schutz, Caitlin, McClure, Barbara J, Sutton, Rosemary, Dalla-Pozza, Luciano, Moore, Andrew S, Greenwood, Matthew, Kotecha, Rishi S, Fong, Chun Y, Yong, Agnes S. M, Yeung, David T, Breen, James, White, Deborah L

“…B-cell acute lymphoblastic leukaemia (B-ALL) is a haematological malignancy driven by diverse genomic alterations, the most common being gene fusions, which…”
Get full text